More recently in April 2024, the FDA granted tumor-agnostic approval for trastuzumab deruxtecan in the treatment of all unresectable or metastatic solid tumors exhibiting HER2 3+ expression, based on the findings from the DESTINY-PanTumor02 trial [7,146]. The gene discussed is ERBB2; the disease is neoplasm.